Indoco Remedies Limited stock analysis

The Master Manufacturing Plan has been implemented successfully in our manufacturing sites and we expect to get manufacturing efficiency, which will help us remain compititive in export market. Continued investments in automation, infrastructure upgrades and capacity expansion are expected to improve 171 productivity, enhance operational resilience and reinforce Indoco’s long-term cost competitiveness, supporting sca

Backed by resilient legacy brands, a growing portfolio of high-performance franchises and a robust pipeline of differentiated products, Indoco Pharma is well-positioned to sustain its growth momentum. The Division remains focused on expanding the market leadership, strengthening portfolio resilience and delivering sustainable long-term value creation for all stakeholders. 159 Indoco SPADE The Indoco SPADE division re

Through its strategic partnerships, Indoco now holds a portfolio of 28 approved ANDAs in the U.S. Indoco has secured three new marketing authorizations in UK and four new marketing authorizations in EU for Group Companies, thereby strengthening its EU & UK business. Indoco secured new registrations in Emerging markets spread over countries of AFRICA, ASEAN, MENA, LATAM, CIS & FWA regions.

We also expanded our consumer healthcare footprint with the launch of toothpaste in South Africa. These achievements reflect our growing capability to deliver differentiated products across global markets while strengthening our international presence. Sustainability continues to be an integral part of our long- term growth strategy, guiding the way we create value for our stakeholders while fulfilling our responsibi

International formulations contributed 35% of the quarter 1 FY27 revenue at INR1,451 million, while our active pharmaceuticals business delivered a stellar performance this quarter, surging to 42% Y -o-Y and a turnover of INR522 million. With consistent growth, this platform provides crucial backward integration f or our formulations pipeline, ensuring both cost competitiveness and supply chain security. Looking ahea

Baddi III, which is the large plant which makes paracetamol, again, in the range of 70%, 75%, if I'm not mistaken. So, all the incremental as we expand our quarterly exports to INR200 crores mark will lead to higher efficiency and margin expansion? So this is -- this quarter inability to supply has not resulted in the top line.

This strategic initiative provides a clear roadmap for sustainable growth and operational excellence across all manufacturing sites. Quality And Compliance Focused Indoco's state-of-the-art manufacturing facilities are approved by some of the most respected regulatory agencies in the world, including the USFDA, UKMHRA, EDQM, TGA - Australia, WHO GMP , SAHPRA - South Africa, etc. Committed To Quality, Driven By Precis

Sudarshan Padmanabhan: Sure, ma'am. One last question before I join the queue is one is, of course, operating leverage, but do you see any areas where we can reduce the costs, improve the efficiency given that we have seen challenges as far as growth is concerned? So you must have -- you remember, we must have spoken earlier about our Master Manufacturing Plan, whereby we increased efficiency in the plant, increased

Shareholders/Members are requested to participate on first come first serve basis as participation through VC/OAVM is limited and will be closed on expiry of 15 (fifteen) minutes from the scheduled time of the Annual General Meeting. Shareholders/Members with >2% shareholding, Promoters, Institutional Investors, Directors, KMPs, Chairman of Audit Committee, Nomination and Remuneration Committee and Stakeholders’ Rela